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INTRODUCTION
According to the statistical yearbook of the Ministry of 
Health and Welfare, crude colorectal cancer incidence rates in 
Korea in 2008 were 54.7 and 36.9 per 100,000 among males 
and females, respectively. Colorectal cancer is thus the second 
most common cancer in males and the fourth most common 
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cancer in females.
1 The mortality rates (the number of deaths 
per 100,000 people, %) of colorectal cancer in 2008 were 
15.4% among males and 12.1% among females. Colorectal 
cancer is thus the fourth most common cause of cancer death 
among Korean males and the second most common cause of 
cancer death among Korean females. The age-standardized 
mortality rates of colorectal cancer continue to increase, un-
like those of other common cancers, including lung cancer, 
liver cancer and stomach cancer, whose mortality rates have 
decreased in recent years. Increases in the incidence of colo-
rectal cancer may be partly due to Westernization of many 
Koreans’ lifestyles. Greater public awareness of colorectal can-
cer and the addition of colorectal cancer in 2004 to the na-
tional cancer screening program are likely also responsible in 
part for the increased incidence rates. Participation rates in 
the national colorectal screening program increased from ap-
proximately 10% in 2004 to over 20% in 2008. In 2009, the 
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statements were draw by systematic reviews and meta-analyses. Herein we discussed epidemiology of colorectal cancers and adenomas 
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participation rate was 25.9%, and more than 1.1 million pa-
tients were screened.
2 
Because most cases of colorectal cancer occur after the pro-
longed transformation of adenomas into carcinomas, early 
detection and removal of colorectal adenomas are effective 
methods of secondary prevention of colorectal cancer. Ad-
vanced adenomas are clearly precancerous lesions and serve 
as surrogate markers of colorectal cancer (the ultimate target 
of secondary prevention).
3 Survival rates of colorectal cancer 
in Korea have increased in recent years due to higher rates of 
screening and improved colorectal cancer treatment. Before 
2000, the survival rate was approximately 50%, the rate in-
creased to 66.3% between 2001 and 2005 and to 70.1% be-
tween 2004 and 2008. These results are consistent with data 
from other countries indicating that the early detection of 
colorectal cancer by screening in asymptomatic, average-risk 
adults has reduced mortality rates from this disease.
4-6 Con-
sidering the increasing incidence of colorectal cancer and 
polyps, it is important to establish policies on colorectal can-
cer screening and polyp detection that are suitable for the Ko-
rean population.
In this report, we discuss methods of preventing colorectal 
cancer by detecting advanced adenomas based on the concept 
of the adenoma-carcinoma sequence. The report will discuss 
the use of fecal occult blood testing (FOBT) for large-scale 
colorectal cancer screening and the use of endoscopic and ra-
diologic tests to identify polyps and other structural changes 
in the colorectal mucosa that occur at the early stages of carci-
nogenesis.
Purpose
The guidelines outlined in this report were established for 
asymptomatic, average-risk adults without a personal history 
of colorectal cancer, clinical signs and symptoms suspicious 
for colorectal cancer or a family history suggesting a high risk 
of colon cancer. Systematic reviews of existing colorectal can-
cer screening guidelines in Western countries and of the pub-
lished domestic and foreign literature regarding colorectal 
cancer screening were performed. Meta-analyses were con-
ducted in some cases to evaluate the timing, methods, bene-
fits and limitations of the tests for colorectal cancer screening 
and polyp detection. The ultimate goal of this report is to aid 
practicing physicians. People with symptoms or signs sugges-
tive of the presence of colorectal cancer or polyps do not fall 
within the scope of these guidelines; such individuals should 
undergo appropriate diagnostic testing. Although epidemio-
logic data have been obtained through Korean multi-center 
studies over the past decade, these studies alone were not felt 
to provide sufficient information for the establishment of 
colorectal cancer screening and polyp detection guidelines. 
To better reflect the reality of medical care in Korea, opinions 
of domestic experts and endoscopic specialists responsible for 
colorectal cancer screening were collected to evaluate the lev-
els of evidence on the screening of colorectal cancer and de-
tection of polyps.
Limitations in the guidelines for colorectal cancer 
screening and polyp detection
The Korean literature on colorectal cancer screening and 
polyp detection is quite limited. Therefore, most of the evi-
dence used in this report comes from Western guidelines 
and systematic reviews. Although the results of major studies 
performed since 2006 were reviewed, the quality of evidence 
(even among similar studies) based on the grade assessment 
method was quite low. This was generally due to heterogene-
ity among the different trials regarding important elements 
such as the risk of colorectal cancer, demographic differences 
among patients, qualitative and quantitative differences among 
screening tests and a lack of standardized test methods. To 
overcome these limitations and reflect the different approach 
to polyp care and the different health care environment in 
Korea, web-based questionnaire surveys were conducted. 
Furthermore, using the Delphi method, the extent of agree-
ment regarding the guidelines was determined by asking a 
number of domestic experts to participate in a series of round-
table discussion to formulate a consensus on policies regard-
ing colorectal cancer screening and polyp detection.
 
Development of clinical practice guidelines for 
colorectal cancer screening and polyp detection
In May 2010, a committee tasked with the development of 
clinical practice guidelines for colorectal cancer screening and 
polyp detection was organized. The committee consisted of 
nine practice committee members and two consultants from 
the three major Korean gastroenterology societies: the Korean 
Society of Gastroenterology (KSG), the Korean Society of 
Gastrointestinal Endoscopy (KSGE) and the Korean Associa-
tion for the Study of Intestinal Diseases (KASID). The consul-
tants were Professor Hyo Jong Kim (Kyung Hee University 
School of Medicine), representing the KSGE and the KASID, 
and Professor Suk-Kyun Yang (University of Ulsan College of 
Medicine), representing the KSG. At the first meeting in June 
2010, the Development Committee appointed a chairman, 
Hyun-Soo Kim (Yonsei University Wonju College of Medi-
cine), and a secretary, Dong-Hoon Yang (University of Ulsan 
College of Medicine). The committee was divided into three 
teams: one associated with colorectal cancer screening and 
colorectal polyp detection (Team leaders: Hyun-Soo Kim 
from Yonsei University Wonju College of Medicine; Bo In Lee 
from The Catholic University of Korea College of Medicine; BI Lee et al. 
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Seong-Eun Kim from Ewha Womans University School of 
Medicine; and Sung Pil Hong from Yonsei University College 
of Medicine), one associated with surveillance (Team leaders: 
Young-Ho Kim from Sungkyunkwan University School of 
Medicine; Sung Noh Hong from Konkuk University School 
of Medicine; and Dong-Hoon Yang from University of Ulsan 
College of Medicine), and one associated with treatment 
(Team leaders: Dong Il Park from Sungkyunkwan University 
School of Medicine; Suck Ho Lee from Soonchunhyang Uni-
versity College of Medicine; and Sung Jae Shin from Ajou 
University School of Medicine). Between June and July 2010, 
during the first and second workshops, the committee mem-
bers learned methodologies for guideline development from 
various experts, including Professor Hyeong-Sik Ahn, the 
chairman of the Korean Medical Guideline Advisory Com-
mittee of the Korean Academy of Medical Science. The com-
mittee members shared experiences in the process of clinical 
practice guideline development with Professor Joong-Wonk 
Park (Department of Internal Medicine, National Cancer 
Center), Professor Eun Sook Lee (Department of Surgery, 
National Cancer Center) and Professor Byong Duk Ye (De-
partment of Gastroenterology, University of Ulsan College of 
Medicine). Thereafter, the methods, scope, schedule and di-
rection of the clinical practice guideline development were 
discussed. It was decided to adapt evidence-based foreign 
guidelines for screening and surveillance to avoid unneces-
sary duplication of effort. Revisions were made to fit our 
practice situation, and some topics were subject to meta-anal-
ysis and systematic review using the newest data. Because 
there were no relevant foreign guidelines for endoscopic trea-
tment for colorectal polyps, it was decided to develop new 
guidelines based on systematic literature reviews and meta-
analyses. In September 2010, Professor Hyun Jung Kim (De-
partment of Preventive Medicine, Korea University College of 
Medicine) was invited to share her opinions on guideline de-
velopment methodologies, systematic literature review and 
meta-analysis. 
Key questions were identified by the practice committee 
and were organized, to the extent possible, according to the 
Patient, Intervention, Comparison and Outcome format. 
Each question was investigated by performing a literature 
search, and evidence tables for each key question were made. 
The screening test team selected clinical practice guidelines or 
recommendations for adaptation. The team considered whet-
her the guidelines had been written in English and took into 
account the American or European society who developed 
them. Evidence tables were included and evaluated with the 
Appraisal of Guidelines for Research & Evaluation II tool. 
From this analysis, 10 recommendations were extracted. In 
December 2010, Professor Se Hyung Kim (Department of 
Radiology, Seoul National University College of Medicine) 
and Professor Hae Jeong Jeon (Department of Radiology, 
Konkuk University School of Medicine), who are experts in 
computed tomography (CT) colonography and the use of 
double-contrast barium enemas (DCBEs) for colorectal can-
cer screening, joined the committee as a team member and a 
consultant representing the Korean Society of Abdominal Ra-
diology, respectively. To investigate the screening, surveillance 
and endoscopic treatment of polyps in Korea, questionnaire 
surveys were conducted between January and February 2011 
among 263 members of the KASID. The results of the ques-
tionnaire can be utilized as a comparative indicator of future 
adherence to the new guidelines. In April 2011, the results of 
the surveys were presented at the spring conference of the 
KASID. In addition, keypad voting was conducted in April 
2011 during the spring symposium of the Korean Societies of 
Gastroenterology Association. The voting was performed be-
fore and after presenting evidences and foreign guidelines on 
various aspects of screening, surveillance, and endoscopic 
treatment to assess the influence of education on clinicians’ 
decisions regarding the management of polyps. In July 2011, 
drafts of key phrases were completed with the help of external 
experts, and 45 experts gathered to determine the extent of 
agreement using the Delphi method. The expert panels con-
sisted primarily of councilors and current members of the 
KSG, the KSGE and the KASID, as well as 11 members of the 
Korean Society of Abdominal Radiology. Final key phrases 
for the developed guidelines were chosen when over 50% 
agreement was obtained. The determination of 50% agree-
ment was made when the sum of responses of ‘completely 
agree,’ ‘mostly agree’ and ‘partially agree,’ based on the five-
level Likert scale, was greater than 50%. The draft of the re-
port obtained official approval from the multiple societies in-
volved in polyp management after a public hearing that was 
held in August 2010. The evidence bases of the key phrases 
were presented in a seminar of the KSGE. The final report 
was announced at the autumn conference of the KSG in No-
vember 2011. There was no conflict of interest among any of 
the committee members participating in the development 
process of these clinical practice guidelines.
 
Distribution and implementation of the guidelines
The developed guidelines will be co-published in the jour-
nals of the KSG, the KSGE, the KASID and the journal of the 
Korean Society of Radiology. The guidelines will also be pub-
lished through the websites of the relevant societies and in 
major medical newspapers. Additionally, the contents will be 
widely distributed through summary guidebooks to training 
hospitals. 28  Clin Endosc 2012;45:25-43
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Feedback after guideline implementation and 
revisions
After a certain amount of time has passed after the distri-
bution and implementation of the guidelines, adherence to 
the guidelines in clinical practice will be assessed. Further-
more, the contents will be periodically revised to reflect the 
latest clinical knowledge.
METHODS
Selection of key questions
To support the need for establishing Korean clinical prac-
tice guidelines, key questions regarding the epidemiology of 
colorectal cancer and polyps in Korea were chosen. Key ques-
tions also included whether FOBT, CT colonography, DCBE 
or colonoscopies are appropriate colorectal cancer screening 
and colorectal adenoma detection methods. Information re-
garding risk factors for colorectal cancer and polyps is con-
tained in the appendix.
Literature search
Literature regarding screening tests was sought using two 
search databases, Medline’s PubMed and the National Guide-
line Clearinghouse (NGC), and one secondary literature 
search engine, Trip. Because NGC is a database where only 
guidelines have been collected, three key terms (colorectal 
cancer, screening and diagnosis) were searched together, and 
links that included all three search terms were investigated to 
review major guidelines, including those of the USA and the 
European Union. In PubMed, clinical trials published in Eng-
lish from January 2006 to June 2010 were searched using the 
following sets of key words: 1) “colon adenoma,” “colon neo-
plasm,” “colon polyp” or “colorectal cancer”; 2) “screening,” 
“asymptomatic” or “average risk”; and 3) key words for each 
screening test method. The terms “colonoscopy” or “sigmoid-
oscopy” were searched separately to compare each screening 
method. Regarding epidemiology investigations, the key 
word, “Korean” was used; for FOBT tests, “fecal occult blood 
test,” “FOBT,” “FIT,” and “fecal immunochemical test” were 
used; for CT colonography, “CT colonography,” “CTC,” “vir-
tual colonoscopy,” “VC,” and “colonography, computed tomo-
graphic” were used; and for double-contrast barium enema 
(DCBE), “double contrast barium enema,” “barium study,” 
and “DCBE” were used. Limits based on the study design and 
the quality of each paper were excluded based on opinions 
collected from the practice committee. 
A total of 6,304 papers from the world literature (1,409 on 
epidemiology, 833 on FOBT, 201 on CT colonography, 45 on 
DCBE, 2,743 on sigmoidoscopy and 1,073 on colonoscopy) 
were identified. Overlapping papers were excluded, and pa-
pers that did not meet the selection criteria were excluded by 
reviewing the paper titles or the full texts of abstracts. When 
necessary, the suitability of the materials was judged by re-
viewing the full texts of the papers. Finally, 148 papers (26 on 
Fig. 1. Study selection. DCBE, double-contrast barium enema; CTC, computed tomography colonography; FSG, flexible sigmoidoscopy; CS, 
colonoscopy; RCT, randomized controlled trial.
Articles reviewed for the development of colorectal cancer screening and polyp detection guidelines
For 
epidemiology Total searched articles
· Studies from references in previous guidelines
· Studies from PubMed
· Studies from KoreaMed, KISS, and KMbase
·   Articles excluded after review of abstracts  
or full texts
· Articles selected for final detailed review
n=126
n=26
6 guidelines
3 meta-analyses
17 clinical trials
· n=42
· n=1,367
· n=10
For stool study
n=112
n=24
3 guidelines
2 RCTs
2 meta-analyses
17 clinical trials
· n=16
· n=817
· n=8
For DCBE
n=27
n=18
18 observational     
studies
· n=0
· n=45
· n=0
For CTC
n=169
n=32
3 meta-analyses
29 observational     
studies
· n=80
· n=121
· n=0
For FSG
n=108
n=29
3 guidelines
3 RCTs
1 meta-analyses
22 clinical trials
· n=16
· n=2,727
· n=4
For CS
n=24
n=19
4 guidelines
15 clinical trials
· n=16
· n=1,057
· n=10BI Lee et al. 
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epidemiology, 24 on FOBT, 32 on CT colonography, 18 on 
DCBE, 29 on sigmoidoscopy and 19 on colonoscopy) were 
chosen. Literature search methods by subtitle are shown in 
Fig. 1, and standardized evidence tables were prepared to ex-
tract data corresponding to individual key questions from the 
selected pieces of literature.
Meta-analysis
Meta-analyses were conducted on FOBT and CT colonog-
raphy. All studies included in the analyses were observational 
studies. To minimize clinical heterogeneity among the stud-
ies, studies with similar groups of enrolled subjects and test 
methods were selected. 
The sensitivity and specificity of FOBT for colorectal cancer 
and advanced colorectal adenomas compared to colonoscopy 
were calculated. Meta-analyses were conducted to compare 
detection rates for colorectal cancer and polyps between the 
traditional guaiac FOBT and the FIT and between one-time 
and two-time FIT methods. To minimize heterogeneity am-
ong studies, analyses were limited to studies that were similar 
in terms of the enrolled subjects, state of rehydration, sam-
pling methods, number of tests and positive thresholds. For 
these meta-analyses, the odds ratios (OR) of polyp detection 
rates were calculated for the two test methods and for the 
number of tests conducted. For CT colonography, 9 papers 
published since 2,000 describing studies only among asymp-
tomatic, average-risk patients were selected through literature 
searches, and meta-analyses were conducted on these papers. 
Details of the literature search methods, literature assessments 
and development of the evidence table are presented in the 
appendix (Supplementary Table 1).
The sensitivity and specificity of each test method were cal-
culated from papers in which the true positive, false positive, 
true negative and false negative rates for polyp detection com-
pared with colonoscopies could be calculated. Papers that did 
not present the individual values were excluded from the 
analyses. When the I
2 value of the analysis was over 50% or 
when the results of Cochran’s Q-test showed p-values <0.1, 
the results for sensitivity and specificity were assessed as hav-
ing statistical heterogeneity. The tool used to analyze the diag-
nostic accuracy of each test was Meta-disc 1.4 (The Ramón y 
Cajal Hospital, Madrid, Spain); for other meta-analyses, Re-
view Manager version 5.1 (The Cochrane Collaboration, Ox-
ford, UK) was used.
Quality of evidence and strength 
of recommendations
Recommendations are presented based on a systematic re-
view of the selected literature and meta-analyses. The quality 
of evidence, indicating the degree of scientific evidence that 
each recommendation has, and the strength of the recom-
mendation were determined following the methodology pro-
posed by the Grading of Recommendations Assessment, De-
velopment and Evaluation Working Group (Table 1).
7,8
The quality of evidence was assessed to be “high” when the 
evidence consisted of randomized controlled trials and “low” 
when evidence included observational studies. However, in 
cases where studies used as evidence had limitations in the 
study design or execution, inconsistent results, indirect evi-
dence, imprecise results or publication bias, the quality of evi-
dence was adjusted downward. In cases of observational stud-
ies where large effects were observed, where reported effects 
might have been reduced due to confounding variables or 
where dose-response gradients existed, the quality of evi-
dence was adjusted upward. The strength of each recommen-
dation was assessed as “strong” or “weak” by considering the 
balance of desirable and undesirable consequences, the quali-
ty of the evidence, the confidence in the values and the refer-
ences and the effective allocation of medical expenses and re-
sources. That is, in cases where it was judged that following a 
specific recommendation would lead to significant health 
benefits or losses for most patients, the strength of the recom-
Table 1. Quality of Evidence and Strength of Recommendations
Quality of evidence
High quality  Further research is very unlikely to change our confidence in the estimate of the effect.
Moderate quality  Further research is likely to have an important impact on our confidence in the estimate of the effect  
  and may change the estimate.
Low quality  Further research is very likely to have an important impact on our confidence in the estimate of the  
  effect and is likely to change the estimate.
Very low quality  Any estimate of effect is very uncertain.
Strength of recommendation
Strong recommendation Most or all individuals will be best served by the recommended course of action.
Weak recommendation Not all individuals will be best served by the recommended course of action. There is a need to  
  consider more carefully than usual individual patient’s circumstances, preferences, and values.30  Clin Endosc 2012;45:25-43
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mendation was classified as “strong.” The strength of the rec-
ommendation was classified as “weak” in cases where it was 
judged that following the recommendation would lead to im-
portant benefits or loss in terms of the quality of the health of 
patients but where differences existed among patients, thus 
leading to the need to consider individual environments, 
preferences and values.
7,8
EPIDEMIOLOGY OF COLORECTAL 
CANCERS AND COLORECTAL 
ADENOMAS IN KOREA
In Korea, is the incidence rate of colorectal cancer increasing?
In Korea, the incidence rate of colorectal cancer is in-
creasing.
·Quality of evidence: low
· Level of agreement: completely agree (87%), general-
ly agree (13%), partially agree (0%), generally dis-
agree (0%), totally disagree (0%)
Colorectal cancer has historically been one of the most 
common cancers in Western countries. However, the inci-
dence rate has recently been increasing in some Asian coun-
tries due to the Westernization of lifestyles and increases in 
the obese population. The prevalence rates of colorectal can-
cer are rapidly increasing in Korea, too. According to 2002 
data, the age-standardized incidence rates of colorectal cancer 
had rapidly increased in Asian countries to 49.3 per 100,000 
in Japan, 24.7 in Korea and 35.1 in Singapore. For compari-
son, colorectal cancer rates are 44.4 per 100,000 in North 
America and 42.9 in Europe. In East Asian countries, colorec-
tal cancer was the third most common cancer among both 
males and females.
9 According to the Korea Central Cancer 
Registry, the age-standardized incidence rate of colorectal 
cancer in 1999 was 21.2 per 100,000 and has been increasing 
every year by 6.3% to 31.7 in 2005 and 35.1 in 2008.
1,2,10-12 
Among males, the age-standardized incidence rate of colorec-
tal cancer has been increasing every year by 6.9% from 27.0 
per 100,000 in 1999 to 47.0 in 2008. Among females, the inci-
dence of colorectal cancer has been increasing every year by 
5.2% from 17.1 in 1999 to 25.6 in 2008. In 2008, colorectal 
cancer thus became the second and fourth most common 
cancer among males and females, respectively. Whereas can-
cer mortality rates have been decreasing for stomach and liver 
cancer, the cancer mortality rate has been increasing for colo-
rectal cancer. Colorectal cancer corresponded to the third 
most common cause of cancer death among males and the 
fourth among females in Korea.
In Korea, is the incidence rate of colorectal adenomas in-
creasing?
In Korea, the incidence rate of colorectal adenomas is 
increasing.
·Quality of evidence: very low
· Level of agreement: completely agree (53%), general-
ly agree (35%), partially agree (5%), generally dis-
agree (5%), totally disagree (2%)
In Korea, the incidence rate of colorectal adenomas is also 
increasing in proportion to the rapid increase in colorectal 
cancers. According to a previous retrospective study, among 
2,435 adults aged 50 or more who underwent a screening 
colonoscopy between 1998 and 2004, colorectal adenomas 
were found in 30.2% and advanced adenomas in 4.1% of pa-
tients.13 Among males, adenomas and advanced adenomas 
were found in 35.9 and 5.1% of patients, respectively. Adeno-
mas and advanced adenomas were found in 18.7 and 2.0% of 
female patients, respectively. The prevalence rates of colorec-
tal adenomas were therefore higher among males. In a recent 
prospective multicenter study conducted among 2,307 adults 
aged 50 or more who underwent a screening colonoscopy 
during 2003 or 2004, colorectal adenomas and advanced ade-
nomas were found in 40.5 and 2.5% of patients, respectively.
14 
Adenoma prevalence rates in Korea were similar to the West-
ern rates of 25% to 38%, whereas advanced adenoma preva-
lence rates were lower than the Western rates of 6.1% to 
10.5%.
15,16 When corrected for age, however, the prevalence 
rates of advanced adenomas were similar to those in the 
West.
13 
Colorectal cancer screening and polyp detection test 
guidelines
Time for screening tests 
1) Based on studies of screening tests, are prevalence rates of 
colorectal cancers or colorectal adenomas higher in average-
risk groups aged 50 or more compared to those aged less 
than 50?
It is recommended to begin colorectal cancer screening 
test and colorectal adenoma detection test from the age of 
50 in average-risk groups. However, those who have 
symptoms or signs that lead to the suspicion of colorectal 
cancers should receive appropriate diagnostic tests re-
gardless of age.
·Quality of evidence: low
· Strength of recommendation: strong recommenda-
tionBI Lee et al. 
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· Level of agreement: completely agree (42%), general-
ly agree (50%), partially agree (5%), generally dis-
agree (3%), totally disagree (0%)
The incidence rates of colorectal cancer and colorectal ade-
noma increase with age. According to the 2008 statistics of 
the Korea Central Cancer Registry, the incidence rates of 
colorectal cancers by age group were 28.8 per 100,000 in peo-
ple aged 40 to 49, 82.5 in those aged 50 to 59, 174.5 in those 
aged 60 to 69 and 245.7 in those aged 70 or more. Thus, the 
incidence rates rapidly increased in people aged 50 or more.
1 
Compared to those aged 40 to 49, the risk of advanced adeno-
mas increased in people aged 50 to 54 by a factor of 1.82 (95% 
confidence interval [CI], 1.38 to 2.40), in people aged 55 to 59 
by a factor of 2.38 (95% CI, 1.81 to 3.14) and in people aged 60 
to 66 by a factor of 2.91 (95% CI, 2.21 to 3.83). The detection 
rates of advanced adenomas were therefore high when sc-
reening colonoscopies were conducted in populations aged 
50 or more.
17 According to a prospective study of colonoscopy 
screenings conducted in 11 Asian countries, the prevalence 
rates of colorectal neoplasia and advanced neoplasia were 
23.9 and 5.8%, respectively, in people older than 50, while the 
rates were 11.2 and 2.0%, in groups aged less than 50, indicat-
ing that the prevalence rates of colorectal neoplasia rapidly 
increase in individuals aged 50 or older. In Korea, whereas the 
prevalence rates of colorectal adenomas and advanced adeno-
mas were 14.3% to 22.6% and 1.1% to 1.6%, respectively, in 
asymptomatic, average-risk people under 50, the rates were 
29.8% to 40.5% and 2.5% to 3.7% in those aged 50 or more.
13,14 
Based on the aforementioned evidences, the colorectal cancer 
screening and polyp detection tests are generally recom-
mended in individuals with average risk at the age of 50 or 
more. However, those who have symptoms or signs that lead 
to the suspicion of colorectal cancers or polyps should receive 
appropriate diagnostic tests, including a colonoscopy, regard-
less of age.
Screening tools
1) FOBTs
The FOBT is a method of detecting blood in the stool, a 
finding that may suggest the presence of tumors in the large 
intestine. The advantage of FOBT is that it is relatively simple, 
cheap and non-invasive. Thus, this test has been adopted as 
an effective mass screening test for colorectal cancer in most 
foreign guidelines. Prior to the development of immuno-
chemical methods in the 1970s and their commercialization 
in the 1980s,
4 guaiac-based tests were the most common 
types of FOBTs. Although many studies have examined the 
usefulness of the FOBT for colorectal cancer screening, the 
detection rates have varied due to differences in test methods, 
including whether diets are restricted before testing, the num-
ber of samples collected per test, and whether the stool speci-
men is rehydrated.
(1) Among average-risk adults aged 50 and older, do colorec-
tal cancer incidence rates and mortality rates decrease in 
groups who had received a FOBT for colorectal cancer screen-
ing compared to groups who had not?
In average-risk adults aged 50 and older, FOBT is rec-
ommended as a large-scale colorectal cancer screening 
test. This is based on the premise that any positive test 
should be followed up with colonoscopy.
·Quality of evidence: moderate quality
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (50%), general-
ly agree (33%), partially agree (11%), generally dis-
agree (6%), totally disagree (0%)
The sensitivity for diagnosing colorectal cancer in asymp-
tomatic, average-risk groups ranged from 12.9% to 37.1% for 
one-time testing with an unrehydrated Hemoccult II test, a 
traditional guaiac based FOBT (gFOBT), to 79.4% for He-
moccult SENSA testing, a high-sensitivity gFOBT.
18-21 How-
ever, the specificity for diagnosing colorectal cancer tends to 
be lower for the Hemoccult SENSA test than for the tradi-
tional gFOBT. According to a study that compared the results 
of gFOBT with those of sigmoidoscopy, specificity for 
colorectal cancer was 97.7% for Hemoccult II and 86.7% for 
Hemoccult SENSA.
21 The integrated sensitivity of high-sensi-
tivity gFOBT for colorectal cancer calculated through a meta-
analysis was 74.5% (61.0% to 85.3%), and the specificity was 
88.1% (87.6% to 88.7%).
18,21-23 Meanwhile, when FITs was used 
as a colorectal cancer screening test in asymptomatic, aver-
age-risk groups, the integrated sensitivity calculated by meta-
analysis was 73.0% (63.4% to 80.8%), and the specificity was 
94.8% (94.6% to 95.1%) (Fig. 2, Supplementary Fig. 1).
18,23-25
The sensitivity can be increased by repeating the gFOBT. 
Based on the results of a meta-analysis of three observational 
studies on FITs, the diagnostic accuracy for colorectal ad-
vanced neoplasia, including colorectal cancer and advanced 
adenomas, was significantly higher in cases where the test was 
repeated two times than in cases where the test was perfor-
med only once (OR, 1.46; 95% CI, 1.34 to 1.60; p<0.01).
25-28 
Fig. 2 show details of this analysis.
Despite the fact that the sensitivity and specificity of the 
gFOBT for colorectal cancer are low compared to those of 
colonoscopy, the gFOBT is a useful population screening test 
for colorectal cancer. According to studies in which patients 32  Clin Endosc 2012;45:25-43
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were followed for 8 to 13 years, the gFOBT reduced colorectal 
cancer mortality by 15% to 30%.
29-31 According to a cohort 
study that tracked patients for 18 years, the gFOBT increases 
the rate of colonoscopies, removal of adenomas, and detec-
tion of precancerous lesions of colorectal cancer. Consequent-
ly, the FOBT is associated with an up to 20% decrease in 
colorectal cancer incidence rates.
32 Although on a relatively 
small scale, a cohort study in 42,150 subjects followed for 13 
years showed that FITs reduced colorectal cancer mortality by 
70% and significantly reduced progressive colorectal cancer 
incidence rates.
33 All of these studies are based on the impor-
tant premise that when fecal guaiac tests show positive results, 
colonoscopies are performed. That is, any positive FOBT 
should be followed up with colonoscopy to allow early diag-
nosis and treatment of the lesions and reduce colorectal can-
cer mortality. 
The sensitivity of FOBT for colorectal adenomas is very low 
compared to that of colonoscopies. In asymptomatic average-
risk groups, the sensitivity for advanced adenomas was 44% 
(35.5% to 52.0%)
18,23 for the Hemoccult SENSA test, a highly 
sensitive guaiac test, and 24% (21.6% to 27.5%)
18,23-25 for FITs. 
The specificities for advanced colorectal adenomas were 90% 
(89.5% to 91.1%) for the Hemoccult SENSA test and 95% 
(94.9% to 95.4%) for FIT, respectively. Therefore, FOBT is not 
appropriate for colorectal adenoma detection.
(2) In average-risk adults aged 50 and older, is FIT superior to 
the traditional gFOBT as a colorectal cancer screening test? 
In average-risk adults aged 50 and older, FIT is recom-
mended as a colorectal cancer screening test prior to tra-
ditional gFOBT. 
·Quality of evidence: low
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (46%), general-
ly agree (49%), partially agree (3%), generally dis-
agree (2%), totally disagree (0%)
To judge whether FIT is superior to traditional gFOBT as a 
colorectal cancer screening test in average-risk groups, the di-
agnostic sensitivity, convenience and patient compliance as-
sociated with the tests should be examined. Although many 
studies have been conducted to determine the relative accura-
cy of different tests for colorectal cancer, there are difficulties 
in comparing these studies because most of them are obser-
vational, and subject characteristics and test methods are het-
erogeneous. In a meta-analysis that compared detection rates 
between traditional gFOBT and FIT in asymptomatic aver-
age-risk groups, the diagnostic accuracy for colorectal cancer 
was higher for FIT (OR, 1.88; 95% CI, 1.04 to 3.40; p=0.04) 
(Fig. 3).
23,25,34 However, fewer studies have compared colorec-
tal cancer detection rates between high-sensitivity FOBT 
Fig. 3. Meta-analysis comparing guaiac based fecal occult blood testing and fecal immunochemical test in the detection of colorectal can-
cer in average-risk groups. gFOBT, guaiac based fecal occult blood testing; CI, confidence interval.
gFOBT FIT Odds ratio (Non-event) Odds ratio (Non-event)
Study of subgroup Events Total Events Total Weight M-H, fixed, 95% CI M-H, Fixed, 95% CI
Park et al.,25 2010 8 760 20 770 46.7% 2.51 (1.10, 5.73)
Smith et al.,23 2006  9 2,351 12 2,351 53.3% 1.34 (0.56, 3.17)
Total (95% CI) 3,111 3,121 100.0% 1.88 (1.04, 3.40)
Total events 17 32
Heterogeneity: chi2=1.07, df=1 (p=0.30); I2=6%
Test for overall effect: z=2.10 (p=0.04)      0.01            0.1                 1                 10              100
            Favours control    Favours experimental
2 tests 1 test Odds ratio Odds ratio
Study of subgroup Events Total Events Total Weight M-H, fixed, 95% CI M-H, Fixed, 95% CI
Park et al.,25 2010 213      770 182     770   15.1% 1.24 (0.98, 1.55)
Rosen et al.,26 2009 227     330 175     330     6.3% 1.95 (1.42, 2.68)
Rosen et al.,27 2010 925   1,682 700   1,682   36.1% 1.71 (1.50, 1.96)
Grazzini et al.,28 2009 476 20,596 379 20,596   42.5% 1.26 (1.10, 1.45)
Total (95% CI) 23,378 23,378 100.0% 1.46 (1.34, 1.60)
Total events 1,841 1,436
Heterogeneity: chi2=14.94, df=3 (p=0.002); I2=80%
Test for overall effect: z=8.74 (p<0.00001)      0.01            0.1                 1                 10              100
            Favours control    Favours experimental
Fig. 2. Meta-analysis of the detection rate of fecal immunochemical test (FIT) for advanced colorectal neoplasms according to the number 
of samples (1 test vs. 2 tests). CI, confidence interval.BI Lee et al. 
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(Hemoccult SENSA) and FIT. According to a study in 2,351 
subjects, the results of the two tests were not significantly dif-
ferent (OR 1.75, 95% CI 0.73 to 4.19, p=0.21).
4,23 For evaluat-
ing the superiority between high-sensitivity FOBT and FIT, 
additional studies are needed.
The issue of which FOBT test method is the most useful 
should also be considered in terms of test convenience and 
compliance. Guaiac tests measure blood peroxidase in stool 
and the results are influenced by diet, drugs taken and rehy-
dration of stool specimens. To increase diagnostic accuracy, 
the test should be repeated 2 to 3 times. In guaiac tests, false 
positive results may be produced if aspirin or non-steroidal 
anti-inflammatory drugs have been taken within 7 days be-
fore testing and if meat or fish has been ingested within 3 days 
before testing. False-negative results may be produced if vita-
min C has been taken because vitamin C interrupts peroxi-
dase reactions. Thus, vitamin C preparations of 250 mg or 
more, fruits and juices should be avoided for three days be-
fore the test. Rehydration consists of adding a drop of water to 
the slide containing the stool sample before the test. Although 
rehydration increases sensitivity, it is generally not recom-
mended because it can raise the number of false-positive re-
sults and lead to unnecessary additional tests.
4,35 
FITs measure antibodies specific to the globin moiety of 
human hemoglobin, and results are not affected by diet or 
drug ingestion. Furthermore, because globin is degraded by 
digestive enzymes in the upper gastrointestinal tract, FITs are 
more specific for lower gastrointestinal hemorrhage, thereby 
enhancing the accuracy of the test for colorectal cancer.
35,36 
Diverse commercialized FITs are available, and the optimal 
number of stool samples, sample methods, cutoff values, and 
other specifications should be followed according to the man-
ufacturers’ recommendations. Although FIT is relatively more 
expensive than traditional gFOBT, compliance with FIT is 
52.7%. This is significantly higher than compliance with tra-
ditional gFOBT at 43.9%,
22 which may be due to the advan-
tages listed above, particularly due to the increased conve-
nience. 
2) CT colonography 
CT colonography, also known as “virtual colonoscopy,” has 
rapidly evolved along with significant advances in CT imag-
ing technologies. The fundamental elements of CT colonog-
raphy include fecal and fluid tagging, bowel preparation, co-
lonic distention, CT scanning, interpretation and reporting. 
The aforementioned elements are important for successful 
CT colonography. Before the CT colonography examination, 
the patient should take laxatives for proper cleansing of the 
colon, and radioopaque contrast media should be given to la-
bel the residual fluid and fecal material. The importance of 
proper colonic distention during CT colonography cannot be 
overstated. Both supine and prone scans should be routinely 
obtained. The CT colonography usually takes approximately 
10 minutes at the CT scanner. No sedation is required, and 
patients have the capability to return to work the same day. 
Recently, research has been performed regarding non-cathar-
tic approaches to minimize the inconvenience of bowel prep-
aration, but these techniques are not yet sufficiently validated. 
(1) In average-risk groups aged 50 and older, can CT colo-
nography be recommended for colorectal cancer screening 
and polyp detection?
In average-risk groups aged 50 and older, CT colonog-
raphy is recommended as one of the colorectal cancer 
screening and polyp detection methods.
·Quality of evidence: low
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (27%), general-
ly agree (34%), partially agree (26%), generally dis-
agree (13%), totally disagree (0%)
For the detection of colon cancer and advanced adenoma, 
which is the primary goal of screening for colorectal cancer, 
recent data suggest that CT colonography is comparable to 
colonoscopy when state-of-the-art techniques are applied.
37-47 
According to a study of 1,233 asymptomatic average-risk 
adults, the per-patient sensitivity of CT colonography for ade-
nomas of 10 mm or larger was 94%. The specificity was 96%, 
which was higher than the 88% sensitivity of colonoscopy.
37 
However, in two later trials, the diagnostic sensitivities of CT 
colonography in patients with adenomas of 10 mm or larger 
were 55 and 59%, which were much lower than those demon-
strated in the earlier studies.
48,49 These two studies are limited, 
however, because they did not evaluate screening in an as-
ymptomatic population, nor did they use the latest CTC tech-
niques. According to 2005 and 2009 meta-analyses that in-
cluded 33 and 47 prospective studies, respectively,
38,39 on a 
per-patient basis, the pooled sensitivity and specificity of CT 
colonography for large polyps (≥10 mm) were 83% to 85% 
and 92% to 97%, respectively, and 60% to 70% and 90% to 
93% for 6 to 9 mm polyps. Thereafter, a trial was initiated by 
the American College of Radiology (ACR) Imaging Network 
to assess the performance of CT colonography in an asymp-
tomatic average-risk group. This study was conducted in a 
large screening cohort of 2,531 patients at 15 leading institu-
tions in the USA. State-of-the-art techniques used for almost 
all cases in the trial included oral contrast tagging, colonic 
distention with automated CO2 insufflators, multi-detector 
CT (≥16 slices) and 3D polyp detection on a dedicated CT 34  Clin Endosc 2012;45:25-43
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colonography software system.
40 Based on the results, the per-
patient sensitivity and specificity for detecting 10 mm or larg-
er adenomas were 90% and 86%, respectively. The corre-
sponding rates for 6 mm or larger adenomas were 78% and 
88%, respectively. The diagnostic performance of CT colo-
nography can be greatly affected by the techniques used, and 
results improved when multi-detector row CT with thinner 
slice collimation and the 3D fly-through were used.
38 In this 
respect, the ACR recommends using appropriate bowel 
preparation, optimized imaging and interpretation tech-
niques for CT colonography.
50 The prerequisites for facilitat-
ing quality implementation of and patient safety with CT 
colonography in Korea include proper bowel preparation, 
adequate insufflation, appropriate use of a multi-detector 
row CT scanner and low-dose CT colonography technical 
parameters, and a dedicated software system for CT colo-
nography. Interpretation of CT colonography must be per-
formed by adequately trained radiologists on endoscopically 
confirmed CT colonography cases.
According to the results of a meta-analysis of data from 
nine studies conducted only in asymptomatic average-risk 
groups after 2000,
37,40-47 the per-patient diagnostic sensitivity 
of CT colonography for polyp detection was 78% to 100%, 
and the sensitivity increased as polyps became larger. The 
pooled sensitivity was 91.3% for 10 mm or larger polyps and 
82.2% for 6 mm or larger polyps. The per-polyp sensitivity of 
CT colonography was 60% to 100%, which was also enhanced 
as polyps became larger. The pooled per-polyp sensitivity was 
87.2% for 10 mm or larger polyps and 75.4% for 6 mm or 
larger polyps. The per-patient diagnostic specificity of CT 
colonography was 80% to 99% for 6 mm or larger polyps. 
Specificity was similar regardless of polyp size. The results of 
Fig. 4. Meta-analysis of reported sensitivity and specificity in the included studies by polyp size. (A) Per-patient sensitivity for computed to-
mography (CT) colonography. (B) Per-patient specificity for CT colonography. (C) Per-polyp sensitivity for CT colonography. CI, confidence 
interval.
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the meta-analysis are described in detail in Fig. 4.
Furthermore, because the risk for colonic perforation or 
bleeding is extremely low, CT colonography is also a safe and 
noninvasive method.
37,40,44,47,51-54 It has been reported that if 
CT colonography is used for screening, the risk of perfora-
tion among asymptomatic subjects is very low. Based on 
analyses of eight studies regarding perforation after CT colo-
nography,
37,40,44,47,51-54 only 2 cases (0.009%) and 7 cases 
(0.06%) of perforation were reported in two multicenter stud-
ies from 11 and 16 institutions, respectively.
53,54 The frequency 
of major perforation is therefore lower than that of colonos-
copies (0.1%).
4 Among the total 9 cases of colorectal perfora-
tion, only one case occurred in an asymptomatic adult under-
going a screening test, indicating that complications rarely 
occur in CT colonography. In particular, colonic distention 
with low-pressure carbon dioxide delivery may be safer than 
manual insufflation of room air.
55 
Because CT colonography produces CT images not only of 
the colon but also of the upper and lower abdomen, there is a 
chance that incidental extracolonic findings will be detected. 
The results of 11 CT colonography studies, where lesions out-
side the colon were mentioned,
37,40,44,47,56-63 show that the rate 
of detection of extracolonic lesions in CT colonography rang-
es from 18 to 98% and that the incidence of lesions with ‘high’ 
clinical significance ranged from 2% to 35%. The incidence of 
clinically significant extracolonic lesions in the asymptomatic, 
average-risk population is approximately 4.5%.
57 Patients may 
benefit from early detection and treatment of 5.5-cm-or-larg-
er aortic aneurysms or extracolonic malignant neoplasms. In 
many other cases, CT colonography may lead to increased 
costs associated with additional examinations, added radia-
tion exposure, and unnecessary additional tests. Accordingly, 
conducting CT colonography using doses of 50 mAs or lower 
is becoming common.
CT-related radiation exposure may be one of the limita-
tions of CT colonography. According to a recent report issued 
by the Health Physics Society in the USA, the health effects of 
low-dose radiation exposure (defined as below 50 to 100 mSv) 
were considered to be “either too small to be observed or are 
nonexistent.”
64 However, due to the rapid increase in imaging 
technologies, the frequency of radiographic examinations 
during a typical individual’s lifetime has increased. Multiple 
radiation exposures can be sufficiently high to be of concern. 
If a 50-year-old individual undergoes a CT colonography test 
with an estimated dose of 7 to 13 mSv, his or her lifetime risk 
of colorectal cancer will be 0.044%, and the risk of the occur-
rence of cancer in any site will be 0.14%.
65 Recently, as low-
dose CT colonography has become common, it has been re-
ported that if tests are conducted using a four-channel multi-
detector CT at a dose of 50 mAs, the radiation dose can be 
reduced to 5 to 8 mSv. Low-dose tests are therefore strongly 
recommended.
66
As mentioned above, due to its good diagnostic perfor-
mance and safety profile, CT colonography was suggested as 
a screening test for colorectal cancer and polyps in the 2008 
revised colorectal screening guidelines jointly published by 
the American Cancer Society (ACS), the US Multi-Society 
Task Force on Colorectal Cancer (USMSTF), and the ACR.
4 
In Korea, limitations in the facilities have thus far prevented 
the implementation of CT colonography as a population-
based screening method. However, because CT colonography 
is a minimally invasive, whole-colon structural examination 
with high diagnostic performance, it will likely rapidly ex-
pand in Korea as it has in the rest of the world.
(2) When a polyp 6 mm or larger is identified on CT colonog-
raphy, is a colonoscopy necessary? 
In the case that a polyp 6 mm or larger is found in CT 
colonography, a colonoscopy is recommended.
·Quality of evidence: very low
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (78%), general-
ly agree (22%), partially agree (0%), generally dis-
agree (0%), totally disagree (0%)
There is consensus that all patients with one or more polyps 
larger than 1 cm or with three or more 6 to 9-mm lesions 
identified on CT colonography should be referred for colo-
noscopy.
4,67 However, the management of patients with two or 
fewer 6 to 9 mm indeterminate polyps remains controversial. 
Variable prevalence rates of advanced adenomas among pa-
tients with 6 to 9 mm polyps have been reported. Recent stud-
ies conducted in a screening population reported the preva-
lence of advanced adenomas to be 2.7% to 5.3%, lower than 
the 10 % prevalence found among the high-risk popula-
tion.68 Regarding the natural history of 6 to 9 mm polyps, 
many pre-1990 studies that used colonoscopy or DCBE re-
ported that only some of the 6 to 9 mm polyps grew during 
surveillance. In general, the size did not change and even de-
creased in some cases.
69-72 In a recent study using CT colo-
nography, when 128 cases of 6 to 9 mm polyps were followed 
for an average of 1.4 years, only 12 polyps (9.4%) became 
larger. The remaining polyps did not change in size, became 
smaller or disappeared.
73 However, a limited number of stud-
ies have evaluated the natural history of polyps in this size 
range, and additional large population-based studies are nec-
essary. In conclusion, based on the results from previous 
studies and until further evidence is available to provide addi-
tional guidance, a reasonable approach at this time for pa-36  Clin Endosc 2012;45:25-43
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tients with 6 to 9 mm polyps identified on CT colonography 
is to recommend colonoscopy. Patients who decline colonos-
copy or who are not good candidates for colonoscopy should 
be offered follow-up surveillance with CT colonography or 
colonoscopy.
There are limited studies on surveillance periods in patients 
with negative CT colonography results. Furthermore, the op-
timal management of patients with 5 mm or smaller polyps 
detected on CT colonography is controversial, and experts 
have thus recommended different policies.
67,74,75 The risk of 
advanced adenoma in 5 mm or smaller polyps is very low. In 
a recent study of a screening cohort, the prevalence of ad-
vanced adenoma in patients with 5 mm or smaller polyps was 
1.7%. Given the low risk of 5 mm or smaller polyps and the 
high sensitivity (at least 80%) of CT colonography for 6 mm 
or larger polyps,
11,37,40-47 5 year surveillance using CT colonog-
raphy or colonoscopy is recommended. 
3) DCBE 
DCBE is an imaging technique that evaluates the entire co-
lon by coating the mucosal surface with high-density barium 
and distending the colon with air introduced through a thin, 
flexible catheter that is inserted into the rectum. Multiple ra-
diographic images are obtained from various positions during 
direct fluoroscopic evaluation. The test takes approximately 
10 to 20 minutes. Although patients may experience discom-
fort during or after the examination, sedation is not necessary, 
and the patient can return to daily life immediately after the 
examination. 
(1) In average-risk groups aged 50 and older, can DCBE be 
recommended as a colorectal cancer screening test?
In average-risk groups aged 50 and older, DCBE is rec-
ommended as one of the colorectal cancer screening tests. 
·Quality of evidence: low
·Strength of recommendation: weak recommendation
· Level of agreement: completely agree (19%), general-
ly agree (6%), partially agree (33%), generally dis-
agree (36%), totally disagree (6%)
Much of the literature describing the diagnostic perfor-
mance of DCBEs is limited by a retrospective study design 
and lack of results from an asymptomatic, average-risk 
group.
76-88 Many studies assessing the detection rate of colon 
cancer using DCBE analyzed all patients in an institution- or 
population-based database who had been diagnosed with co-
lon cancer and had been assessed with a prior DCBE within a 
certain period of time. In most studies, the sensitivity for 
DCBE in detecting colon cancer was reported as 85% to 
97%.
76-88 However, a recent study showed a rate of new or 
missed colon cancer after DCBE of 22.4%, demonstrating 
that the diagnostic performance of DCBE was affected by 
several factors, including the quality of the study or the per-
son who performed the study.
89 Comparing different studies 
regarding the performance of DCBE in diagnosing polyps is 
more difficult owing to heterogeneous study designs. In par-
ticular, thresholds of target lesion size, morphologic classifica-
tion, and histopathologic correlation often varied across the 
studies. According to the two studies performed in asymp-
tomatic patients under surveillance due to a history of prior 
polypectomy, the sensitivity of DCBE was 48% for 10 mm or 
larger adenomas and 53% for 6 to 9 mm adenomas.
90,91 In one 
study, DCBE detected six out of eight polyps that were patho-
logically shown to be advanced adenomas (75% sensitivity).
92 
Among 470 patients without polyps on colonoscopy, 83 had 
positive findings on DCBE, yielding a specificity of 82.3%.
91 
Given the low sensitivity of DCBE to polyps, DCBE is not ap-
propriate as a polyp screening method. Furthermore, because 
the diagnostic performance of DCBE in diagnosing colorectal 
cancer and polyps can be affected by many factors, appropri-
ate quality control should precede the test. That is, patients 
should be educated regarding adequate bowel preparation. 
During the examination, patients should be imaged both in 
the prone and supine positions. The entire colon should be 
evaluated in the absence of any retained barium or collapse of 
segments of the colon. The examination should be performed 
by radiologists or radiology residents and trained technicians 
under the supervision of a radiologist.
Colorectal perforation related to DCBE is very rare. Out of 
1,987 patients who underwent DCBE, no cases of colorectal 
perforation occurred.
93 In a large survey conducted among 
board-certified radiologists in the UK, the rate of colorectal 
perforation was one per 25,000 cases (0.004%), and the rate of 
perforation was around one per 10,000 cases.
94 These rates are 
lower than that of perforation after colonoscopy (0.1%).
4 
Therefore, DCBE is advantageous in that it can be conducted 
even in patients where colonoscopies are contraindicated or 
have failed. DCBE can also be used to evaluate the entire large 
intestine. Thus, DCBE can provide a full colonic examination 
for patients in whom colonoscopy has failed or is contraindi-
cated.
DCBE was adopted as a colorectal cancer screening test 
method in 1997 by the ACS based on its high sensitivity for 
colorectal cancer, accessibility and non-invasiveness.
95 It is 
still used as one of the colorectal cancer screening test meth-
ods in many revised guidelines.
4,96 However, the use of DCBE 
for colon cancer screening continues to decline, and it is time 
to reconsider its role in the future.
4,96 At present, DCBE can be 
regarded as a screening option, particularly in areas where 
colonoscopy resources are limited or when colonoscopy is BI Lee et al. 
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contraindicated or unsuccessful.
(2) In cases where a 6 mm or larger polyp has been found in 
DCBE, is a colonoscopy necessary?
In cases where a 6 mm or larger polyp has been found 
in DCBE a colonoscopy is recommended.
·Quality of evidence: very low
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (79%), general-
ly agree (21%), partially agree (0%), generally dis-
agree (0%), totally disagree (0%)
Studies regarding the management of colorectal lesions de-
tected by DCBE are limited. According to the 2008 revised 
colorectal screening guidelines jointly published by the ACS, 
the USMSTF and the ACR, in cases where one or more 6 mm 
or larger polyps are found by DCBE, an additional colonos-
copy is recommended.4 Furthermore, no direct evidence ex-
ists (except with respect to the use of stool guaiac tests) re-
garding surveillance periods for colorectal cancer and polyp 
screening in such patients.
97 According to a recent report in a 
screening population, the probability of advanced adenomas 
developing from 5 mm or smaller polyps is as low as 1.7%. 
Given the low sensitivity of DCBE for detecting polyps, in pa-
tients without colorectal lesions or who have been found to 
have 5 mm or smaller polyps, 5 year surveillance using CT 
colonography or colonoscopy is recommended. 
4) Colonoscopy 
Screening colonoscopy is advantageous because it allows 
the entire colon to be examined at once, and adenomas or 
early cancers found during the examination can be removed. 
Screening colonoscopy also requires bowel preparation, and 
the quality of preparation significantly affects the quality of 
the examination. During colonoscopy, conscious sedation is 
usually performed to minimize pain and discomfort. Perfora-
tion may occur during colonoscopy at a frequency of approxi-
mately 0.09%,
98 mainly in relation to polypectomy. 
Although it is clear that colonoscopy can detect colorectal 
polyps effectively and even remove polyps, it cannot be said 
to be a perfect test. According to reports, colonoscopy can 
miss between 6 and 12% of 1 cm or larger adenomas
99,100 and 
up to 5% of colorectal cancers.
99,101 In a Korean study, the 
colonoscopy miss rate for adenomas was 17.7%.
102 Thus, 
qualified colonoscopy is very important to minimize the miss 
rate.
Colonoscopic withdrawal times should average at least 6 
minutes in cases where no biopsy or polypectomy is per-
formed.
103 The KSGE’s Quality Control and Assessment on 
National Cancer Screening Program also recommends a mean 
colonoscopic withdrawal time of 6 minutes or longer.
104 Ac-
cording to one study, colonoscopies performed with mean 
withdrawal times of 6 minutes or more resulted in higher de-
tection rates of advanced neoplasia compared with those with 
mean withdrawal times of less than 6 minutes (6.4% vs. 
2.6%).
105 In another study, colonoscopists with higher or low-
er polyp detection rates could be identified based on their 
mean withdrawal time around 6 minute.
106 In a study con-
ducted in Korea, colonoscopic withdrawal time and polyp 
detection rates of gastroenterology fellows were also signifi-
cantly correlated.
107 
However, because the length, angulations, and degree of 
bowel preparation can vary by patients and adenoma detec-
tion abilities differ by endoscopist, colonoscopic withdrawal 
time cannot be the only way to assess the quality of a colonos-
copy. The most important quality metric is the adenoma de-
tection rate of each endoscopist. In fact, the adenoma detec-
tion rate among endoscopists was inversely related with the 
risk of interval colorectal cancer.
108
(1) In average-risk groups aged 50 and older, can screening 
colonoscopy decrease colorectal cancer incidence and its re-
lated mortality?
In average-risk patients aged 50 and older, colonoscopy 
is recommended with priority for colorectal cancer 
screening and polyp detection.
·Quality of evidence: low
· Strength of recommendation: strong recommenda-
tion
· Level of agreement: completely agree (74%), general-
ly agree (20%), partially agree (6%), generally dis-
agree (0%), totally disagree (0%)
Unlike the case of screening sigmoidoscopy, there has been 
no randomized controlled trial to assess whether screening 
colonoscopy can reduce colorectal cancer incidence and its 
related mortality. However, FOBTs and sigmoidoscopy de-
crease colorectal cancer incidence and its related mortality 
by removing precancerous lesions or early cancers with colo-
noscopic. Thus, it can be indirectly assumed that colonosco-
py and polypectomy will reduce colorectal cancer incidence 
and its related mortality. 
According to the National Polyp Study of the United States, 
the colorectal cancer incidence decreased by 76% to 90% in a 
cohort that underwent colonoscopy and polypectomy com-
pared to three other reference populations.
3 Additionally, in-
dividuals living in regions where more colonoscopies were 
performed had lower incidences of colorectal cancer mortali-
ty.
109 Case-control studies and cohort studies showed that 38  Clin Endosc 2012;45:25-43
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colonoscopy and polypectomy reduced colorectal cancer-re-
lated mortality by approximately 65% compared to con-
trols.
110,111
However, this effect may be lower in the right colon than in 
the left colon. The reasons for the decreased rates of colorectal 
cancer prevention by colonoscopy in the right colon include 
biological differences between right-sided and left-sided col-
orectal cancers,
112 failure to detect lesions due to poor bowel 
preparation or inadequate observation.
113 Therefore, to visual-
ize lesions in the right colon, adequate preparation and obser-
vation technique are very important.
(2) When the index colonoscopy for colorectal cancer screen-
ing and polyp detection is negative in an average-risk group 
aged 50 and older, is there any significant difference in colorec-
tal cancer incidence between cases where a follow-up colo-
noscopy was performed five years or longer afterwards and 
cases where a follow-up colonoscopy was performed within 
5 years?
In average-risk patients aged 50 and older, if no colorec-
tal cancer or colorectal adenoma is found at the time of 
the qualified index colonoscopy, follow-up colonoscopy is 
recommended five years later. However, in patients with 
alarming symptoms or with a high risk of interval cancer, 
surveillance may be performed earlier than 5 years.
·Quality of evidence: very low
·Strength of recommendation: weak recommendation
· Level of agreement: completely agree (20%), general-
ly agree (65%), partially agree (9%), generally dis-
agree (6%), totally disagree (0%)
Studies regarding the appropriate interval of the follow-up 
colonoscopy in cases where index colonoscopy is negative are 
still insufficient. Some of the recommendations are based on 
indirect evidence from sigmoidoscopy studies.
114,115
In many cohort studies and case-control studies, when the 
index colonoscopy was negative, the incidence of colorectal 
cancer or advanced adenomas remained low for at least 5 
years.
116-121 According to the results of a cohort study con-
ducted in Germany,
116 among 533 participants with a negative 
screening colonoscopy, no colorectal cancers occurred during 
an average surveillance period of 11.9 years, and the incidence 
of advanced adenoma was significantly lower than in patients 
who did not undergo colonoscopy for at least 10 years. There-
fore, if no colorectal adenomas or colorectal cancers are found 
during screening colonoscopy among average-risk patients 
aged 50 and older, it is appropriate to wait for at least five 
years to perform the next examination. It should be noted 
that the low rates of colorectal tumors after negative colonos-
copy were reported in well-designed prospective cohort stud-
ies conducted in several thousand subjects. In these studies, 
colonoscopies were mainly performed by experts in gastroin-
testinal endoscopy. However, according to the Canadian col-
orectal cancer registry, 2% to 9% of the patients with colorec-
tal cancer had a history of colonoscopy during the 7 to 36 
months prior to diagnosis, suggesting that colorectal cancer 
after colonoscopy is not so rare.
122,123 Because these results are 
from retrospective case-control studies where colonoscopy 
was mainly performed by primary care physicians, the results 
have important implications in Korea, where a great deal of 
colorectal cancer screening is performed in primary care in-
stitutions. Therefore, considering the incidence of post-colo-
noscopy colorectal cancer, follow-up colonoscopy may be 
conducted sooner than 5 years after colonoscopy in patients 
with alarming symptoms or with a higher risk of interval 
cancer.
There is still no evidence regarding the appropriate follow-
up after screening colonoscopy with suboptimal bowel prepa-
ration. Most gastroenterologists tend to advance follow-up 
rather than to repeat the examination.
124 A retrospective study 
reported high miss rates among 216 patients who had colo-
noscopy with suboptimal bowel preparation followed by 
colonoscopy with optimal bowel preparation within 3 years. 
In this report, the adenoma miss rate was 42%, and the ad-
vanced adenoma miss rate was 27%.
125 Therefore, in cases 
where bowel preparation is insufficient, earlier follow-up colo-
noscopy may be considered.
5) Sigmoidoscopy 
Sigmoidoscopy is fundamentally similar to colonoscopy 
but examines less of the colon. It is necessary to inform sub-
jects who are undergoing screening sigmoidoscopy that bow-
el preparation is required, a certain degree of discomfort can 
occur during the examination, cancer prevention effects may 
be limited to the extent of the examination, and positive find-
ings on sigmoidoscopy usually result in a referral for colonos-
copy.
126
According to currently available study results,
127,128 colorec-
tal cancer incidence and its related mortality can be reduced 
by screening sigmoidoscopy. Sigmoidoscopy can therefore be 
recommended as one of the possible colorectal cancer screen-
ing and polyp detection methods in average-risk groups aged 
50 or more.
Standard methods for bowel preparation in screening sig-
moidoscopy have not yet been determined. Although oral la-
vage solutions are more effective than enemas,
129,130 1 or 2 so-
dium phosphate enemas are frequently used based on phy-
sician preference.
126,131-133 Although the insertion depth may 
be subjective,
134 it is generally recommended to observe at least 
beyond the splenic flexure or at least 40 cm from the anal BI Lee et al. 
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verge when the endoscope is straightened.
126 
If any adenomas are identified by sigmoidoscopy, it is nec-
essary to recommend colonoscopy regardless of the adenoma 
size because the possibility of proximal tumors increases even 
if the adenoma is small. However, because 2% to 5% of pa-
tients may have advanced neoplasms in the proximal colon 
even without a distal adenoma, colonoscopic examination 
only in patients with positive sigmoidoscopies may miss ad-
vanced neoplasms in the proximal colon.
135 If biopsy is not 
obtained, colonoscopy should be recommended to all patients 
with one or more polyps >5 mm.
136
In cases where screening sigmoidoscopy is negative in av-
erage-risk patients aged 50 and older, it is not essential to per-
form follow-up sigmoidoscopy within 5 years.
114,115,137,138 Data 
are still limited regarding whether the appropriate interval 
between normal sigmoidoscopy exams should be 5 years or 
longer, and preexisting guidelines differ.
126,139 Although it 
seems clear that colorectal cancer prevention effects through 
sigmoidoscopy persist for at least five years, the extent of this 
examination is limited, and the quality of the examination 
may be limited due to such problems as insufficient bowel 
preparation.
In conclusion, because screening sigmoidoscopy has long-
term colorectal cancer-preventing effects,114,115 and be-
cause colonoscopy has less of a protective effect for right-sid-
ed colorectal cancers compared to left-sided cancers,110,140 
sigmoidoscopy is considered to be an effective colorectal 
cancer screening test. However, it is not widely used as a pri-
mary test for colorectal cancer screening and polyp detection 
because it cannot explore the entire colon. Other disadvan-
tages to sigmoidoscopy include the fact that additional ex-
aminations such as colonoscopies are required if the sigmoid-
oscopy is positive and that sigmoidoscopy is less preferred by 
endoscopists and patients. Finally, colonoscopy is relatively 
inexpensive in Korea.
SUMMARY
Epidemiology of colorectal cancer and colorectal adeno-
mas in Korea
(1) In Korea, the incidence rate of colorectal cancer is in-
creasing.
(2) In Korea, the incidence rate of colorectal adenomas is 
increasing.
Colorectal cancer screening and polyp detection test guide-
lines 
1. Time for screening test
(1) It is recommended to begin colorectal cancer screening 
test and colorectal adenoma detection test from the age of 50 
in average-risk groups. However, those who have symptoms 
or signs that lead to the suspicion of colorectal cancers should 
receive appropriate diagnostic tests regardless of age.
2. Fecal occult blood test
(1) In average-risk adults aged 50 and older, FOBT is rec-
ommended as a large-scale colorectal cancer screening test. 
This is based on the premise that any positive test should be 
followed up with colonoscopy. 
(2) In average-risk adults aged 50 and older, FIT is recom-
mended as a colorectal cancer screening test prior to tradi-
tional gFOBT.
3. CT colonography
(1) In average-risk groups aged 50 and older, CT colonog-
raphy is recommended as one of the colorectal cancer 
screening and polyp detection methods.
(2) In the case that a polyp 6 mm or larger is found in CT 
colonography, a colonoscopy is recommended.
4. Double-contrast barium enema
(1) In average-risk groups aged 50 and older, double-con-
trast barium enema is recommended as one of the colorectal 
cancer screening tests.  
(2) In cases where a 6 mm or larger polyp has been found 
in double-contrast barium enema, a colonoscopy is recom-
mended.
5. Colonoscopy
(1) In average-risk patients aged 50 and older, colonoscopy 
is recommended with priority for colorectal cancer screening 
and polyp detection.
(2) In average-risk patients aged 50 and older, if no colorec-
tal cancer or colorectal adenoma is found at the time of the 
qualified index colonoscopy, follow-up colonoscopy is rec-
ommended in five years or later. However, in patients with 
alarming symptoms or with a high risk of interval cancer, 
surveillance may be performed earlier than 5 years.
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